EXEL

41.69

2.33% 0.95

Pre-mercato: 41.20 -0.49 -1.18%

Exelixis Inc (EXEL)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché EXEL Giù? Forum Previsione

Precedente Chiudi:

$40.74

Aprire:

$41.06

Volume 24 ore:

4.21M

Relative Volume:

1.56

Capitalizzazione di mercato:

$10.83B

Reddito:

$2.29B

Utile/perdita netta:

$677.90M

Rapporto P/E:

17.55

EPS:

2.3753

Flusso di cassa netto:

$779.77M

1 W Prestazione:

-6.84%

1M Prestazione:

-2.25%

6M Prestazione:

+11.53%

1 anno Prestazione:

+8.88%

Intervallo 1D:

$40.69

$41.83

Intervallo di 1 settimana:

$39.71

$45.01

Portata 52W:

$32.38

$49.62

Exelixis Inc Stock (EXEL) Company Profile

Nome

Exelixis Inc

Settore

Healthcare (1106)

Industria

Biotechnology (621)

Telefono

(650) 837-7000

Indirizzo

1851 HARBOR BAY PARKWAY, ALAMEDA, CA

Dipendente

1,077

Cinguettio

@exelixisinc

Prossima data di guadagno

2025-07-28

Ultimi documenti SEC

EXEL's Discussions on Twitter

Compare EXEL vs VRTX, REGN, ARGX, ALNY, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
EXEL Exelixis Inc	41.69	10.58B	2.29B	677.90M	779.77M	2.3753
VRTX Vertex Pharmaceuticals Inc	477.89	120.48B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	787.50	81.05B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	749.56	46.33B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	327.30	42.26B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	299.02	32.87B	5.36B	287.73M	924.18M	2.5229

Exelixis Inc Stock (EXEL) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-01-08	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2026-01-05	Downgrade	BofA Securities	Neutral → Underperform
2025-11-18	Iniziato	Wolfe Research	Peer Perform
2025-11-03	Downgrade	Guggenheim	Buy → Neutral
2025-10-21	Aggiornamento	Leerink Partners	Market Perform → Outperform
2025-09-19	Ripresa	Barclays	Equal Weight
2025-09-17	Ripresa	Barclays	Equal Weight
2025-09-17	Iniziato	Goldman	Buy
2025-07-08	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2025-06-24	Aggiornamento	Stephens	Equal-Weight → Overweight
2025-02-24	Downgrade	Wells Fargo	Overweight → Equal Weight
2025-01-27	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2025-01-24	Downgrade	Oppenheimer	Outperform → Perform
2024-12-20	Downgrade	BMO Capital Markets	Outperform → Market Perform
2024-12-17	Downgrade	BofA Securities	Buy → Neutral
2024-10-16	Reiterato	RBC Capital Mkts	Outperform
2024-09-19	Iniziato	UBS	Neutral
2024-04-11	Downgrade	Barclays	Overweight → Equal Weight
2023-12-19	Iniziato	BTIG Research	Buy
2023-12-15	Iniziato	Citigroup	Buy
2023-09-26	Iniziato	H.C. Wainwright	Buy
2023-08-22	Reiterato	Oppenheimer	Outperform
2023-08-08	Iniziato	SVB Securities	Market Perform
2023-07-11	Ripresa	Morgan Stanley	Equal-Weight
2023-05-10	Ripresa	Piper Sandler	Overweight
2023-03-09	Iniziato	Wells Fargo	Overweight
2023-01-26	Iniziato	Credit Suisse	Outperform
2022-10-18	Iniziato	JMP Securities	Mkt Outperform
2022-06-24	Iniziato	BMO Capital Markets	Outperform
2021-11-19	Iniziato	Piper Sandler	Overweight
2021-11-03	Ripresa	Jefferies	Buy
2021-10-07	Iniziato	Jefferies	Buy
2021-08-06	Reiterato	H.C. Wainwright	Buy
2021-06-15	Iniziato	H.C. Wainwright	Buy
2021-05-18	Ripresa	Goldman	Sell
2021-03-31	Iniziato	Credit Suisse	Outperform
2021-03-12	Iniziato	Wolfe Research	Outperform
2020-03-04	Iniziato	Barclays	Overweight
2020-01-13	Iniziato	SunTrust	Buy
2019-11-13	Iniziato	BofA/Merrill	Buy
2019-03-18	Aggiornamento	Morgan Stanley	Underweight → Equal-Weight
2018-09-17	Iniziato	Goldman	Neutral
2018-09-10	Iniziato	Morgan Stanley	Underweight
2018-05-11	Reiterato	Needham	Buy
2017-10-17	Reiterato	Needham	Buy
2017-10-17	Reiterato	RBC Capital Mkts	Outperform
2017-10-16	Reiterato	SunTrust	Buy
2017-09-22	Downgrade	Leerink Partners	Outperform → Mkt Perform
2017-09-15	Iniziato	RBC Capital Mkts	Outperform
2017-09-12	Reiterato	Needham	Buy
2017-07-14	Iniziato	SunTrust	Buy
2017-03-31	Iniziato	Needham	Buy
2017-03-16	Iniziato	Oppenheimer	Perform
2017-02-28	Downgrade	Stifel	Buy → Hold
2016-11-03	Iniziato	Deutsche Bank	Buy
2016-10-10	Aggiornamento	Piper Jaffray	Neutral → Overweight
2016-09-15	Reiterato	Stifel	Buy

Mostra tutto

Exelixis Inc Borsa (EXEL) Ultime notizie

Mar 04, 2026

A Look At Exelixis (EXEL) Valuation As Analyst Optimism Builds Around Its Oncology Pipeline - simplywall.st

Mar 04, 2026

Mar 03, 2026

EXEL: Zanzalintinib advances toward launch as pivotal trials and franchise expansion drive future growth - TradingView

Mar 03, 2026

Forecasting The Future: 11 Analyst Projections For Exelixis - Sahm

Mar 03, 2026

Is Improving Analyst Sentiment Reframing Exelixis (EXEL) Oncology Pipeline As A Core Valuation Anchor? - simplywall.st

Mar 03, 2026

Mar 02, 2026

Exelixis (EXEL) EVP Haley granted 40,459 RSUs vesting from 2027 - Stock Titan

Mar 02, 2026

Exelixis (NASDAQ: EXEL) CEO granted RSUs, gifts 100K shares - Stock Titan

Mar 02, 2026

Exelixis stock falls after rival Merck trial shows better results - Investing.com

Mar 02, 2026

RBC Capital Lowers Exelixis (EXEL) Price Target to $43 | EXEL St - GuruFocus

Mar 02, 2026

Royal Bank Of Canada Issues Pessimistic Forecast for Exelixis (NASDAQ:EXEL) Stock Price - MarketBeat

Mar 02, 2026

Why Exelixis (EXEL) Stands Out as a Leading Value Investment for Long-Term Growth - Bitget

Mar 02, 2026

Exelixis (NASDAQ:EXEL) Shares Down 9.4% After Analyst Downgrade - MarketBeat

Mar 02, 2026

Why Exelixis (EXEL) is a Top Value Stock for the Long-Term - Yahoo Finance

Mar 02, 2026

RBC Lowers Price Target on Exelixis to $43 From $46, Keeps Sector Perform Rating - marketscreener.com

Mar 02, 2026